Guizhou Bailing Group Pharmaceutical Co Ltd002424
▲ ポジティブ技術関連度
Wholly-owned grandchild company received Macau approval to start Phase III clinical trial of its Category 1.1 innovative TCM Tangning Tongluo Tablets.
銘柄への影響 1
その他
Guizhou Bailing Group Pharmaceutical Co Ltdテーマインパクト
カバレッジ外企業 1
澳门济良方有限公司非上場▲ ポジティブ
技術関連度
Macau Jiliangfang Limited received prior approval from Macau's Pharmaceutical Administration Bureau to conduct the Phase III clinical study of Tangning Tongluo Tablets.